CXCR7: A novel tumor endothelial marker in renal cell carcinoma

Pathology International

Volumn 62, Issue 5, 2012, Pages 309-317

  Maishi, Nako ^a   Ohga, Noritaka ^a   Hida, Yasuhiro ^b   Akiyama, Kosuke ^a   Kitayama, Kazuko ^a   Osawa, Takahiro ^a   Onodera, Yuichiro ^a   Shinohara, Nobuo ^b   Nonomura, Katsuya ^b   Shindoh, Masanobu ^a   Hida, Kyoko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CXCR7; Renal carcinoma; Tumor angiogenesis; Tumor endothelial cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; MESSENGER RNA;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR ENDOTHELIAL CELL; UPREGULATION;

AGED; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHEMOKINE CXCL12; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CXCR; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84860292632     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2012.02792.x     Document Type: Article

References (43)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
2. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Suppl 3): 4-10.
3. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004; 4 (Suppl 2): S62-8.
4. Hurwitz H, Fehrenbacher L, Novotny W etal. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
5. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
6. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009; 15: 5020-5.
7. Garber K. Angiogenesis inhibitors suffer new setback. Nat Biotechnol 2002; 20: 1067-8.
8. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003; 361: 1959.
9. Miller KD. E2100: A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3: 421-2.
10. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003; 52: 328-37.
11. Yang JC, Haworth L, Sherry RM etal. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
12. Matsuda K, Ohga N, Hida Y etal. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 2010; 394: 947-54.
13. Ohga N, Hida K, Hida Y etal. Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells. Cancer Sci 2009; 100: 1963-70.
14. Negrier S, Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2011; DOI: 10.1007/s10637-011-9677-6.
15. Escudier B, Eisen T, Stadler WM etal. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.
16. Motzer RJ, Hutson TE, Tomczak P etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
17. Rini BI, Tamaskar I, Shaheen P etal. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-3.
18. Chu TF, Rupnick MA, Kerkela R etal. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.
19. Burns JM, Summers BC, Wang Y etal. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201-13.
20. Iwakiri S, Mino N, Takahashi T etal. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009; 115: 2580-93.
21. Marechal R, Demetter P, Nagy N etal. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009; 100: 1444-51.
22. Mazzinghi B, Ronconi E, Lazzeri E etal. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med 2008; 205: 479-90.
23. Miao J, Wang Z, Provencher H etal. HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci U S A 2007; 104: 17093-8.
24. Wang J, Shiozawa Y, Wang Y etal. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283: 4283-94.
25. Yoshida D, Nomura R, Teramoto A. Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1alpha, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells. J Neuroendocrinol 2009; 21: 481-8.
26. Madden SL, Cook BP, Nacht M etal. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004; 165: 601-8.
27. Maksym RB, Tarnowski M, Grymula K etal. The role of stromal-derived factor-1-CXCR7 axis in development and cancer. Eur J Pharmacol 2009; 625: 31-40.
28. Wurth R, Barbieri F, Bajetto A etal. Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature. J Neuroimmunol 2011; 234: 115-23.
29. Zabel BA, Lewen S, Berahovich RD, Jaen JC, Schall TJ. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol Cancer 2011; 10: 73.
30. Zheng K, Li HY, Su XL etal. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31.
31. Akino T, Hida K, Hida Y etal. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009; 175: 2657-67.
32. Hida K, Hida Y, Amin DN etal. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64: 8249-55.
33. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008; 99: 459-66.
34. Kurosu T, Ohga N, Hida Y etal. HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 2011; 104: 819-29.
35. Muraki C, Ohga N, Hida Y etal. Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells. Int J Cancer 2011; 130: 59-70.
36. Tsuchiya K, Hida K, Hida Y etal. Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 2010; 36: 1379-86.
37. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009; 113: 6085-93.
38. Hartmann TN, Grabovsky V, Pasvolsky R etal. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008; 84: 1130-40.
39. Meijer J, Ogink J, Roos E. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer 2008; 99: 1493-501.
40. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
41. Kijowski J, Baj-Krzyworzeka M, Majka M etal. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 2001; 19: 453-66.
42. Darash-Yahana M, Pikarsky E, Abramovitch R etal. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004; 18: 1240-2.
43. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17: 1159-61.